文献速递血栓与止血

子痫前期中血管性血友病因子/ADAMTS-13轴的改变

Alterations in the von Willebrand factor/ADAMTS-13 axis in preeclampsia.
PubMed 文献 · J Thromb Haemost · 2023-11-04

病例对照研究纳入34例子痫前期和48例正常妊娠,另设12例有子痫前期史的正常妊娠对照。子痫前期VWF抗原升高、ADAMTS-13活性略低、VWF抗原/ADAMTS-13比值升高,该比值>2.7时调整OR为19.2;VWF/ADAMTS-13轴与sFlt-1/PlGF无相关性。

要点

  • 子痫前期VWF抗原中位数3.07 vs 正常妊娠1.87 IU/mL(P<.0001)。
  • VWF抗原/ADAMTS-13比值>2.7时调整OR为19.2。
  • 血小板下降百分比与VWF活性、VWF活性/抗原比值及sFlt-1/PlGF正相关。

核心结论

  • 子痫前期中VWF/ADAMTS-13轴显著改变,作者认为需进一步研究其潜在临床用途。

研究设计与样本

  • 病例对照研究,纳入34例子痫前期和48例正常妊娠,另设12例有子痫前期史的正常妊娠作为额外对照组。
  • VWF抗原和VWF活性采用自动免疫比浊法测定,ADAMTS-13活性采用荧光共振能量转移-VWF73法测定,sFlt-1和PlGF采用酶联免疫吸附法测定。

主要发现

  • VWF抗原子痫前期中位数3.07 vs 正常妊娠1.87 IU/mL(P<.0001)。
  • ADAMTS-13活性子痫前期中位数89.6 vs 正常妊娠94.4 IU/dL(P=.02),无严重缺乏。
  • 子痫前期未观察到VWF活性显著升高,VWF活性/抗原比值中位数0.77 vs 正常妊娠0.97(P<.0001)。
  • VWF抗原/ADAMTS-13比值子痫前期中位数3.42 vs 正常妊娠2.06(P<.0001),比值>2.7(正常妊娠第75百分位)的调整OR为19.2。
  • 有子痫前期史者比值与正常妊娠对照相似;VWF抗原/ADAMTS-13与sFlt-1/PlGF无相关性;血小板下降百分比与VWF活性(P=.01)、VWF活性/抗原比值(P=.004)及sFlt-1/PlGF比值(P=.01)正相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者在结论中提出需进一步研究VWF/ADAMTS-13轴的潜在临床用途。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preeclampsia is a gestational hypertensive disorder characterized by maternal endothelial activation and increased ratio of soluble fms-like tyrosine kinase-1 (sFlt-1) inhibitor to placental growth factor (PlGF). The von Willebrand factor (VWF)/ADAMTS-13 axis is of interest because of the underlying endothelial activation and clinical overlap with pregnancy-associated thrombotic thrombocytopenic purpura. OBJECTIVES: To assess VWF, ADAMTS-13, and VWF/ADAMTS-13 ratio in preeclampsia and look for associations with sFlt-1/PlGF ratio and clinical features. METHODS: Thirty-four preeclampsia cases and 48 normal pregnancies were assessed in a case-control study. Twelve normal pregnancies in women with a history of preeclampsia formed an additional comparator group. VWF antigen (VWF:Ag) and VWF activity (VWF:Ac [VWF:glycoprotein IbM]) were measured via automated immunoturbidimetric assay, ADAMTS-13 activity was measured via fluorescence resonance energy transfer-VWF73 assay, and sFlt-1 and PlGF were measured via enzyme-linked immunosorbent assay. RESULTS: VWF:Ag was higher in preeclampsia than in normal pregnancy (median, 3.07 vs 1.87 IU/mL; P < .0001). ADAMTS-13 activity was slightly lower (median, 89.6 vs 94.4 IU/dL; P = .02), with no severe deficiencies. Significant elevations in VWF:Ac were not observed in preeclampsia, resulting in reduced VWF:Ac/VWF:Ag ratios (median, 0.77 vs 0.97; P < .0001). VWF:Ag/ADAMTS-13 ratios were significantly higher in preeclampsia (median, 3.42 vs 2.06; P < .0001), with an adjusted odds ratio of 19.2 for a ratio of >2.7 (>75th centile of normal pregnancy). Those with a history of preeclampsia had similar ratios to normal pregnant controls. VWF:Ag/ADAMTS-13 and sFlt-1/PlGF were not correlated. However, percentage reduction in platelets correlated positively with VWF:Ac (P = .01), VWF:Ac/VWF:Ag ratio (P = .004), and sFlt-1/PlGF ratio (P = .01). CONCLUSION: The VWF/ADAMTS-13 axis is significantly altered in preeclampsia. Further investigation of potential clinical utility is warranted.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Neave L, Thomas M, de Groot R, et al. Alterations in the von Willebrand factor/ADAMTS-13 axis in preeclampsia. J Thromb Haemost. 2023. PMID: 37926193. doi:10.1016/j.jtha.2023.10.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。